NSRX is the ticker symbol for Nasus Pharma Ltd, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks NSRX with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is NSRX a good stock to buy?

NSRX is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/NSRX.

Where does 13F Pro source NSRX data?

All Nasus Pharma Ltd fundamentals and ownership data come directly from SEC EDGAR. Nasus Pharma Ltd files with the SEC under CIK 2029039. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Nasus Pharma Ltd(NSRX)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Nasus Pharma Ltd (NSRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NSRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 10 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Nasus Pharma Ltd reports quarterly revenue of $1.2B, net income of $-5.9M, an operating margin of -0.4%. Top institutional holders of NSRX by reported 13-F value include BALYASNY ASSET MANAGEMENT L.P., Cable Car Capital, Velan Capital Investment Management, based on the most recent SEC filings. NSRX trades on the NYSE exchange and files with the SEC under CIK 2029039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NSRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nasus Pharma Ltd directly from SEC EDGAR.

Revenue

$1.2B

Net Income

$-5.9M

Free Cash Flow

$-4.9M

Operating Margin

-0.4%

NSRX key financials by period

Nasus Pharma Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	20-F	$1.2B	$-5.9M	-0.4%

Institutions holding NSRX

Institutional investors reporting a position in Nasus Pharma Ltd on SEC Form 13F.
Institution	Shares	Value	Reported
BALYASNY ASSET MANAGEMENT L.P.	898,473	$3.1M	2026-06-30
Cable Car Capital	616,081	$2.2M	2026-06-30
Velan Capital Investment Management	359,390	$1.3M	2026-06-30
Hudson Bay Capital Management	134,771	$471.7K	2026-06-30
Bleichroeder	89,848	$314.5K	2026-06-30
CITADEL ADVISORS	22,004	$77.0K	2026-06-30
XTX Topco Ltd	16,640	$58.2K	2026-06-30
RENAISSANCE TECHNOLOGIES	12,200	$42.7K	2026-06-30
MORGAN STANLEY	1,000	$3.5K	2026-06-30
Caitong International Asset Management , Ltd	4	$14.00	2026-06-30

SEC EDGAR: CIK 2029039 →

Nasus Pharma Ltd

NSRX

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 10 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.